Dr. Noah Brown received a B.S. in Biology from Stanford University in Stanford, California in 1999 and an M.D. from the University of Michigan in 2004. He also pursued both residency and fellowship training at the University of Michigan. His training included a residency in Anatomic and Clinical Pathology (2008-2013), and fellowships in Hematopathology (2011-2012) and Molecular and Genetic Pathology (2013-2014). Dr. Brown is board certified in Anatomic and Clinical Pathology, Hematopathology and Molecular Genetic Pathology and was awarded the Association for Molecular Pathology (AMP) Young Investigator Award. He joined the faculty of the Department of Pathology at the University of Michigan in 2014 as an Assistant Professor. He became Director of the Molecular Diagnostics Laboratory at the University of Michigan in 2015 and is now a Clinical Professor. He has been active in numerous AMP committees including the clinical practice, program and nominating committees, previous Chair of the Molecular Genetic Pathology Program Council and several AMP working groups. He has authored or co-authored more than 70 peer-reviewed articles as well as several book chapters.

Alexis Carter, MD, is an actively practicing Molecular Genetic Pathologist and Physician Informaticist for the Laboratory at Children’s Healthcare of Atlanta and an Adjunct Associate Professor within the Department of Pathology and Laboratory Medicine at Emory University. She is the Program Director for the inaugural Emory Clinical Informatics Fellowship program and is teaching faculty for the American Medical Informatics Association (AMIA) Clinical Informatics Board Review Course for physicians. She is the chair of the Association for Molecular Pathology (AMP) Electronic Health Records and Genomics Working Group and a past AMP secretary/treasurer and past chair of the Informatics Subdivision. She is the current Secretary for the Clinical and Laboratory Standards Institute document development committee for two-dimensional barcoding for both clinical and anatomic pathology laboratory specimens. She was the senior author for the guideline on validation of next-generation sequencing bioinformatics pipelines from AMP, the College of American Pathologists (CAP), and AMIA. She is an Associate Editor for Administrative and Regulatory Affairs for Archives of Pathology and Laboratory Medicine, an editorial board member of the Journal of Pathology Informatics, a former Associate Editor of the Journal of Molecular Diagnostics, and a reviewer for multiple scientific journals in molecular diagnostics, genetics and informatics. She is board certified in clinical informatics, molecular genetic pathology, anatomic pathology and clinical pathology.

Dr. Daniel Diekema is a Professor of Medicine at Tufts University School of Medicine, and Chief of the Infectious Diseases Division at Maine Medical Center in Portland, Maine. He also serves as Medical Director of Epidemiology and Infection Prevention for the MaineHealth system. As a hospital epidemiologist, infectious diseases clinician and clinical microbiologist, Dr. Diekema’s clinical and research interests include the epidemiology and prevention of antimicrobial resistance and healthcare-associated infections, and stewardship of infectious diseases diagnostic testing. He has authored or co-authored over 300 peer-reviewed papers in these subject areas. Dr. Diekema is a past president of the Society for Healthcare Epidemiology of America, and was a member and co-chair of the CDC’s Healthcare Infection Control Practices Advisory Committee.

Ellen Heitzer works at the Institute for Human Genetics in Graz, Austria, where she heads the Research Unit “Liquid Biopsies for Personalized Medicine in Cancer”. Professor Heitzer has a particular research focus on circulating tumor DNA (ctDNA), and her group has developed and implemented a range of analytical approaches to investigate tumor evolution non-invasively and to use ctDNA as a biomarker for therapy response monitoring. In addition, she is actively involved in clinical liquid profiling and plays an important role in molecular tumor boards (MTBs), contributing her expertise to precision oncology decision-making. Her scientific expertise is internationally recognized, as reflected by numerous invitations to speak at international congresses and to contribute reviews to high-impact journals. As a steering committee member of the European Liquid Biopsy Society (ELBS), she actively promotes the standardization and guideline development of liquid biopsy approaches to facilitate their broad clinical implementation. As an EU-registered Clinical Laboratory Geneticist and head of the molecular genetics branch at the D&F Institute for Human Genetics, Professor Heitzer is also involved in routine diagnostics of hereditary diseases, with a particular focus on familial cancer syndromes.

Professor Dame Sue Hill PhD DSc CBiol FSB Hon FRCP Hon FRCPath is the Chief Scientific Officer for NHS England and the head of profession for the 50,000 healthcare science workforce in the NHS and associated bodies – embracing more than 50 separate scientific specialisms. She is a respiratory scientist by background with an international academic and clinical research reputation.
Professor Hill has a broad portfolio of policy responsibilities across NHS England and the wider NHS and provides professional leadership and expert clinical advice across the whole health and care system. In particular, Sue is the Senior Responsible Officer for Genomics in NHS England has established NHS Genomic Medicine Centres and is now leading the NHS England Personalised Medicine strategy.
A significant part of her role involves working across government, with the Department of Health, with the NHS, Public Health and Health Education England and other external stakeholders to inform policy, influence legislation, deliver strategic change and to introduce new and innovative ways of working. Professor Dame Hill sits on our Scientific Advisory Committee and our Research Network Committee.

Susan J. Hsiao, MD, PhD is an Associate Professor in the Department of Pathology and Cell Biology at Columbia University Medical Center. She serves as an Assistant Director and Director of Bioinformatics in the Laboratory of Personalized Genomic Medicine. Her interests include translational research in cancer genomics, improvements in storage and reporting of clinical genomics data, and utilization, coverage and reimbursement of molecular assays. She received her MD and PhD degrees from New York University School of Medicine. She completed residency training in anatomic pathology at New York Presbyterian Hospital/Columbia University Medical Center and completed fellowship training in molecular genetic pathology at University of Pittsburgh Medical Center.

Dr. Sanjat Kanjilal is the Group Leader for the Microbiology Informatics Team at the Amsterdam University Medical Center. Prior to that he was an Assistant Professor at Harvard Medical School. His research interests focus on building a learning health system for infectious diseases and clinical microbiology.

Mark completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. After spending 15 years preparing for a life of academic research, Mark became convinced that revolutionary change in genomics was more likely to emerge from industry. In 2014, he founded Genomenon, an AI-driven genomics company addressing the challenge of connecting clinicians with medical evidence to help diagnose patients with genetic diseases and cancer.

Jonathan Ledermann BSc MD, FRCP FMedSci UCL Cancer Institute, UK Jonathan Ledermann is a Professor of Medical Oncology at UCL Cancer Institute, University College London, and a Consultant Medical Oncologist at UCL Hospitals, London, UK where he has worked for more than 35 years. For 22 years, he was the Director of the Cancer Research UK & UCL Cancer Trials Centre He specialises in the treatment of gynaecological cancers and has led several national and international trials in ovarian cancer. He is a Fellow of the Academy of Medical Sciences in the UK and was a past Vice-President of ESGO and a past chair of the NCRI UK Gynaecological Cancer Trials Group and Rare Tumour Group of the Gynaecological Cancer Intergroup. He has been on Council of IGCS and the BGCS (British Gynaecological Cancer Society). He is the former subject Editor for ESMO Gynaecological Cancer Practice Guidelines. He serves on Editorial Boards of several scientific journals and has published widely in the areas of clinical trials in gynaecological cancers, experimental therapeutics, guidelines, and education in gynaecological malignancies

Neal Lindeman, M.D., is Faculty Distinguished Professor (II) and Vice Chair for Laboratory Medicine and Genomic Pathology at Weill Cornell Medicine. His primary expertise is in Molecular Diagnostics of Cancer, particularly Lung Cancer. He has authored over 200 publications, including the first report of EGFR mutations as determinants of favorable response to treatment with targeted inhibitors in lung cancer, which helped to usher in the era of precision oncology, and the evidence-based practice guidelines for molecular testing in lung cancer jointly developed by three organizations: CAP, AMP, and IASLC. In addition, has guided the development of over two dozen new clinical lab tests, including the world’s first clinical tests for EGFR mutations in Lung Cancer and MYD88 mutations in Waldenstrom’s Macroglobulinemia, and one of the world’s first comprehensive next generation sequencing assays for concurrent assessment of hundreds of genes across all types of cancer. He has received numerous awards for his scientific contributions and practice of Pathology, including the Team Science Award from AACR, the Distinguished Patient Care Award from CAP, and the Gerald Evans Award from ACLPS.

Lili Milani is Head of the Estonian Biobank and Professor of Pharmacogenomics at the University of Tartu. She is part of the core team behind the design and implementation of the national strategy for personalized medicine in Estonia in close collaboration with Tartu University Hospital, the Ministry of Social Affairs, and the Estonian Health Insurance Fund. The expectations for personalized medicine are very high in Estonia, and several implementation projects focusing on genomics for disease prevention have been piloted based on 210,000 genotyped Estonian biobank participants. Most recently, the MyGenome portal was opened for all biobank participants, sharing personalized information on risk for common chronic diseases based on genetics and lifestyle, pharmacogenetic reports and fun facts. In 2024, the Estonian Biobank launched the project of sequencing the genomes of 10,000 biobank participants with PacBio Long Reads. The generated data is expected to benefit research on interindividual variability in drug response, detection of rare and common single-nucleotide and structural variants and contribute to improved personalized medicine.

Dr. Peeter Padrik is a medical oncologist, scientist, and healthcare entrepreneur with more than 30 years of experience in clinical, research, leadership, and healthcare management roles. He has served as the Head of the Haematology & Oncology Clinic, Director of the Cancer Centre at Tartu University Hospital, and Associate Professor of Oncology at the University of Tartu. Dr. Padrik is a medical oncologist with breast cancer patients at Tartu University Hospital, Tartu, Estonia. Dr. Padrik is also a pioneer in incorporating innovative genetic information into healthcare, initially through research projects and academic clinical practice, and is currently the Founder and CEO of Antegenes. Antegenes is a health-tech company, clinic, and lab that develops and implements personalized cancer prevention strategies using innovative clinical genetic tests based on polygenic risk score (PRS) technology. Antegenes has developed into clinical use innovative PRS test for breast cancer and a model for genetics-based personalized breast cancer prevention. Dr. Padrik’s vision and goal are to extend the life expectancy of individuals by integrating genetics-based personalized prevention strategies against common cancers

Dr. Trevor Pugh, PhD, FACMG is a cancer genomics researcher and board-certified molecular geneticist at the forefront of precision medicine. As holder of the Canada Research Chair in Translational Genomics, he uses genome sequencing to understand causes of cancer, guide treatment of patients, and detect early disease using blood tests. He is appointed as Professor in the University of Toronto Department of Medical Biophysics, Senior Scientist at the Princess Margaret Cancer Centre, and Senior Investigator at the Ontario Institute for Cancer Research. He directs the OICR Genomics Program and the Princess Margaret Genomics Centre, genomics cores that specialize in single cell, cell-free DNA and clinically-accredited whole genome sequencing. He has contributed to multiple large-scale genomics and data-sharing programs including The Cancer Genome Atlas, NCI TARGET, AACR GENIE, and the Terry Fox Marathon of Hope Cancer Centres Network. He leads the CHARM Consortium, an initiative to use cell-free DNA monitoring for all people with an inherited predisposition to cancer. Last year, Dr. Pugh was inducted into the Royal Society of Canada College of New Scholars, Artists, and Scientists.

Isabelle Thiffault serves as an Assistant Director of the Clinical laboratory at Children’s Mercy Hospital, Director of Translational Genomics at the Genomic Medicine Center at Children’s Mercy Research Institute since 2014 and professor at The University of Missouri-Kansas City, School of Medicine. She received a Master of Human Genetics from McGill University, Montreal, Canada (2004). She obtained a Doctorate from the Research Centre of the Centre Hospitalier de l’Université de Montréal (2009), and a Postdoctoral Fellowship in Experimental Therapeutics at the McGill University NEURO Institute (2012). Following her postdoctoral position, she completed a three-year clinical fellowship training in molecular genetics (McGill University) and successfully passed the American Board of Medical Genetics and Genomics (ABMGG), examinations in 2015. She has a broad background in genetics and genomics. She is currently part of 5 National Institutes of Health (NIH) grants. Her research at Genomic Answers for Kids (GA4K) focuses on the application of next-generation and genomic tools for molecular diagnosis of rare infantile diseases by the integration of effective computational strategy and functional analysis to characterize the pathogenicity of variants. We have recruited over 18k individuals (>8k families) and surpassed 2,300 rare diagnoses through our groundbreaking work—far out-pacing other rare disease research programs—and continue to conduct cutting-edge science that has led to several “firsts” in the field of genomics research. We have produced > 3000 HiFi long-read genomes, the first to use 5-base sequencing. Following our research initiative, we completed the clinical validation of HiFi genome sequencing, and we were the first center offering it as clinical genomic testing for critically ill patients. Isabelle has published >150 peer-review articles and demonstrates a record of accomplished and productive research projects in an area of high relevance to rare diseases.

Susanna Zucca is Chief Science Officer at enGenome SRL, where she brings deep expertise in genomic data analysis and the development of advanced bioinformatics tools. With a strong academic background, she leads and guides innovative scientific projects, with a particular focus on the integration of generative AI technologies to enhance the interpretation and usability of genomic data.